We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Leica Biosystems Partners with Bio-Techne for Automation of RNAscope COVID-19 Probes on BOND RX Staining Platform

By HospiMedica International staff writers
Posted on 20 Aug 2020
Leica Biosystems (Wetzlar, Germany) and Bio-Techne Corporation (Minneapolis, MN, USA) have entered into a partnership for the automation of RNAscope COVID-19 probes on BOND RX, Leica's staining platform, for research use only. More...


The BOND RX is a flexible, open platform with the capability to run Bio-Techne RNAscope (duplex and multiplex) protocols, allowing for boundless innovation. The RNAscope probes are designed to detect SARS-Cov-2 viral RNA, SARS-Cov-2 viral replication sequences, and cellular receptors targeted by the virus, including ACE2 and TMPRSS2. Researchers now have the ability to automate their COVID-19 research protocols, reducing manual labor and turnaround time.

"The Bio-Techne R&D team quickly developed COVID-19 specific probes when the genetic sequence of this virus was released," said Kim Kelderman, President, Diagnostics and Genomics Segment, Bio-Techne Corporation. "We believe RNAscope probes will enable researchers to gain a greater understanding of the pathogenesis of this disease. The availability of these probes on the automated Leica Biosystems platform will expedite important discoveries."

"We expect the automation of COVID-19 research protocols on BOND RX to enable researchers to achieve breakthroughs faster in their research for vaccines, treatment or other vital areas of investigation," added Melissa Aquino, President, Leica Biosystems. "The partnership with Bio-Techne has enabled us to offer RNAscope COVID-19 probes to our BOND RX customers, which is an example of our commitment to support researchers in addressing the pandemic."

Related Links:

Leica Biosystems
Bio-Techne Corporation

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Vessel Sealing Instrument
ERGOseal
Pediatric Mask
Respire SOFT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: Reusable catheter patients used 35 percent fewer antibiotics compared to their single-use only counterparts. (Photo courtesy of the University of Southampton)

Reusable Intermittent Catheters Reduce Antibiotic Use Without Increasing Urinary Tract Infections

Intermittent self-catheterization, used to empty the bladder several times a day, can leave patients vulnerable to recurrent urinary tract infections and repeated antibiotic use. Reliance on single-use... Read more

Surgical Techniques

view channel
Image: Avvio Medical\'s technology combines microbubble-enhanced acoustic cavitation with smart catheter navigation to precisely target and break down ureteral stones, all without the need for routine stenting or general anesthesia (Photo courtesy of Avvio Medical)

Anesthesia-Sparing System Targets Faster Ureteral Stone Treatment

Ureteral stone care is often delayed by operating room scheduling constraints and growing wait times, leaving a gap between diagnosis and treatment. With no fundamentally new therapeutic approach introduced... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.